Lixisenatide (Lyxumia) is an injectable drug for diabetes that acts as a GLP-1 receptor agonist for controlling blood sugar. It was discovered by the Zealand Pharma A/S in Denmark and licensed and developed by Sanofi Pharmaceuticals. GLP-1 is a natural peptide that is released in blood after eating meal and helps in suppressing the secretion of glucose while simultaneously stimulating insulin secretion by the pancreas. Lixisenatide is injected one a day for the treatment of type 2 diabetes patients, who are incapable of attaining sufficient sugar control with oral diabetes medication or basal insulin.

At the moment, Lixisenatide had been approved in Japan and the European Union for the use of diabetic patients especially those who cannot control the disease with exercise and diet. In the United Kingdom, is only available in the Scotland. In the US, the drug is still under clinical testing is yet to be approved by the US Food and Drug Administration (FDA). However, the American Diabetes Association, the American Association of Clinical Endocrinologists and the American College of Endocrinology is still conducting clinical tests of the said drug. In particular, the drug is being tested for its cardiovascular safety. Pending the clinical test which will last most probably until 2015, Sanofi Pharmaceuticals have pulled its application its FDA approval while awaiting the cardiovascular risk study so as not to preempt the market.

In the Philippines, the drug is still unavailable and is still undergoing testing under the GetGoal-L-Asia Phase III Clinical Trial Program which involved patients from Japan, South Korea, Taiwan, and the Philippines. So far, there have been observed certain side effects of the drug included gastrointestinal adverse reactions, Hypoglycemia, dizziness and headache. In spite of these adverse effects, the effectiveness of the drug as a cure for diabetes continues to be promising.

Related terms:

• lyxumia side effects

Related Posts:

• No Related Posts